Format

Send to

Choose Destination
Lancet Oncol. 2001 Sep;2(9):544-51.

Cyclo-oxygenase 2: a pharmacological target for the prevention of cancer.

Author information

1
Department of Medicine, Weill Medical College of Cornell University and Strang Cancer Prevention Center, New York, USA. ajdannen@med.cornell.edu

Abstract

Understanding the mechanisms underlying carcinogenesis provides insights that are necessary for the development of therapeutic strategies to prevent cancer. Chemoprevention--the use of drugs or natural substances to inhibit carcinogenesis - is an important and rapidly evolving aspect of cancer research. We discuss evidence that cyclooxygenase 2 (COX 2), an inducible form of the enzyme, is a potential pharmacological target to prevent cancer. Key data implicating a causal relation between increased activity of COX 2 and carcinogenesis and possible mechanisms of action of COX 2 in this context are covered. Importantly, selective COX 2 inhibitors appear to be safe enough in human beings to allow large-scale clinical testing in healthy people. Several chemoprevention trials using selective COX 2 inhibitors are underway.

PMID:
11905709
DOI:
10.1016/S1470-2045(01)00488-0
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center